Scynexis Inc (SCYX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1 EVERTRUST PLAZA JERSEY CITY, NJ 07302-6548

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.

Data as of 2021-08-02 08:33:34 -0400
Market Cap143.796 Million Shares Outstanding20.631 Million Avg 30-day Volume255.562 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.39 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.82246 52-week High/Low10.25 / 4.2 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -32.428
Data provided by IEX Cloud
View SEC Filings from SCYX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 2 -50.0% 0 (0.0%) 1 (0.06%) -100.0%
Funds Holding: 42 41 2.44% 14 (0.82%) 13 (0.75%) 7.69%
13F shares: 8.427 Million 10.838 Million -22.25% 3.334 Million 5.425 Million -38.54%
% Ownership 77.0256 56.2157 37.02% 30.4777 28.1382 8.31%
New Positions: 11 14 -21.43% 5 6 -16.67%
Increased Positions 18 15 20.0% 7 5 40.0%
Closed Positions 10 2 400.0% 4
Reduced Positions 3 6 -50.0% 1 2 -50.0%
Total Calls 320.555 Thousand 30.611 Thousand 947.19% 50.1 Thousand
Total Puts 37.922 Thousand 10.1 Thousand 275.47% 15 Thousand
PUT/CALL Ratio 0.12 0.33 -63.64% 0.3 -9.09%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SCYX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SCYX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HANHAM ANN

  • Director
10,000 2021-06-16 2

MACDONALD GUY

  • Director
10,000 2021-06-16 2

GILMAN STEVEN C

  • Director
10,000 2021-06-16 2

HASTINGS DAVID C

  • Director
10,000 2021-06-16 1

ANIDO ARMANDO

  • Director
10,000 2021-06-16 2

TINMOUTH BRIAN PHILIPPE

  • Director
10,000 2021-06-16 2

COYNE CHRISTINE CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-05-10 2

TAGLIETTI MARCO CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2021-01-29 2

ANGULO GONZALEZ DAVID CHIEF MEDICAL OFFICER

  • Officer
0 2021-01-29 2

FRANCOIS ERIC CHIEF FINANCIAL OFFICER

  • Officer
0 2021-01-29 2

SUKENICK SCOTT GENERAL COUNSEL

  • Officer
0 2021-01-29 2

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
No longer subject to file 2021-01-20 2

MACHADO PATRICK

  • Director
0 2019-01-02 0

MCCOURT MARION

  • Director
0 2018-07-02 0

LANGLOIS PATRICK

  • Director
0 2017-01-03 0

RIBEILL YVES J

  • Director
0 2015-07-22 0

WOODALL JONATHAN SEARS INTERIM CHIEF FINANCIALOFFICER

  • Officer
500 2015-07-22 0

PENHOET EDWARD

  • Director
0 2015-06-04 0

KIRBY PAMELA J

  • Director
0 2015-04-01 0

NOTHIAS JEAN-YVES

  • Director
0 2015-04-01 0

OSBORNE, JR. CHARLES F CHIEF FINANCIAL OFFICER

  • Officer
0 2015-04-01 0

SABLE CAROLE CHIEF MEDICAL OFFICER

  • Officer
0 2014-06-18 0

PRUETTE EILEEN GENERAL COUNSEL

  • Officer
0 2014-06-18 0

ARTHAUD LAURENT

  • Director
0 2014-06-11 0

CHAOUI MOUNIA

  • Director
0 2014-06-11 0

FCPR BIOTECHNOLOGY FUND

  • 10% Owner
No longer subject to file 2014-05-07 0

VENTECH CAPITAL II

  • 10% Owner
No longer subject to file 2014-05-07 0

ALTA BIOPHARMA PARTNERS II LP

ALTA BIOPHARMA MANAGEMENT II LLC

ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC

CHAMPSI FARAH

  • 10% Owner
1,286,311 2014-05-07 0

F.C.P.R. GENAVENT

  • 10% Owner
No longer subject to file 2014-05-07 0

SANOFI

  • 10% Owner
1,677,057 2014-05-07 0

DOELLING VIVIAN W VP OF ANIMAL HEALTH

  • Officer
0 2014-05-02 0

GARRETT MICHAEL C VICE PRESIDENT

  • Officer
3,108 2014-05-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

ANIDO ARMANDO - Director

2021-06-21 08:27:37 -0400 2021-06-16 A 10,000 a 10,000 direct

HASTINGS DAVID C - Director

2021-06-21 08:31:01 -0400 2021-06-16 A 10,000 a 10,000 direct

GILMAN STEVEN C - Director

2021-06-21 08:29:00 -0400 2021-06-16 A 10,000 a 10,000 direct

MACDONALD GUY - Director

2021-06-21 08:31:50 -0400 2021-06-16 A 10,000 a 10,000 direct

HANHAM ANN - Director

2021-06-21 08:29:58 -0400 2021-06-16 A 10,000 a 10,000 direct

TINMOUTH BRIAN PHILIPPE - Director

2021-06-21 08:32:38 -0400 2021-06-16 A 10,000 a 10,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SCYNEXIS INC SCYX 2021-08-02 22:15:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 21:45:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 21:15:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 20:45:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 20:15:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 19:45:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 19:15:03 UTC -2.1994 2.2594 15000
SCYNEXIS INC SCYX 2021-08-02 18:45:03 UTC -2.1535 2.2135 15000
SCYNEXIS INC SCYX 2021-08-02 18:15:03 UTC -2.1535 2.2135 15000
SCYNEXIS INC SCYX 2021-08-02 17:45:03 UTC -2.1535 2.2135 15000
SCYNEXIS INC SCYX 2021-08-02 17:15:03 UTC -2.1535 2.2135 15000
SCYNEXIS INC SCYX 2021-08-02 16:45:03 UTC -2.1335 2.2135 15000
SCYNEXIS INC SCYX 2021-08-02 16:15:03 UTC -2.1335 2.2135 10000
SCYNEXIS INC SCYX 2021-08-02 15:45:03 UTC -2.1335 2.2135 10000
SCYNEXIS INC SCYX 2021-08-02 15:15:03 UTC -2.1335 2.2135 10000
SCYNEXIS INC SCYX 2021-08-02 14:45:03 UTC -2.5646 2.6446 15000
SCYNEXIS INC SCYX 2021-08-02 14:15:03 UTC -2.5646 2.6446 15000
SCYNEXIS INC SCYX 2021-08-02 13:45:03 UTC -2.5646 2.6446 15000
SCYNEXIS INC SCYX 2021-08-02 13:15:04 UTC -2.5646 2.6446 15000
SCYNEXIS INC SCYX 2021-08-02 12:45:03 UTC -2.5646 2.6446 15000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments